REXAHN PHARMACEUTICALS, INC.

Company

Opus Genetics, Inc.

Filed

November 10, 2015

Accession Number

0000902664-15-004129

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →